Blueprint Medicines’ Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting

— ASH data reinforce survival benefits of front-line AYVAKIT® (avapritinib) use in patients with advanced SM — — Bone density analyses reported in patients with advanced SM underscore disease-modifying effects of AYVAKIT — CAMBRIDGE, Mass., Dec. 7, 2024 /PRNewswire/ — Blueprint…